Navigation Links
Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
Date:11/12/2009

BALTIMORE, Nov. 12 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has announced that two of its studies regarding its application in oncology drug development and personalized medicine have been selected for a poster and oral presentation at the upcoming AACR-EORTC conference in Boston.

A poster will be presented by Dr. Elizabeth Bruckheimer, Champions' Vice President for Scientific Operations, which will detail the Biomerk Tumorgraft(TM) platform and its characterization. Together the results demonstrate that by maintaining the fundamental genotypic features of the original tumor along with the stromal and cancer stem cell components, the Biomerk Tumorgraft enables identification of the most promising development path for a compound in terms of indication, drug combination, and target patient populations. The platform also has the potential to identify gene pathways of response and resistance as well as prognostic molecular biomarkers. The banking and characterization efforts are performed in collaboration with South Texas Accelerated Research Therapeutics (START).

"The predictive power of the Biomerk Tumorgraft platform is very exciting," said Dr. Bruckheimer. "Application of our models to translational drug development is demonstrating great promise in streamlining the development path of our biotech and pharma partners by giving them a more focused, accelerated and higher probability translational path in clinical trials. Additionally, we are using our platform to build our own oncology pipeline which we expect to yield improved clinical development success rates. We believe that this platform will continue to change the way in which oncology drugs are developed, and oncology patients are treated."

In collaboration, Dr. Manuel Hidalgo, Professor of Oncology at the Universidad CEU San Pablo, Director of the Centro Integral Oncologia "Clara Campal" and Director of the Clinical Research Program at CNIO all in Madrid, Spain and Champions' Chief Scientist will present data regarding prolonged clinical responses from Tumorgraft recommended treatments in patients with refractory advanced cancer, and the ability of the Tumorgraft platform to discover novel predictive biomarkers. He will show the correlation between Tumorgraft response in mice and clinical activity in patients, demonstrating a perfect correlation of sensitivity and response.

Data Presentations:

  • From Mice to Men: Guiding Cancer Treatment through Personalized Tumorgraft(TM) Models Results in Prolonged Clinical Responses in Patients with Refractory Advanced Cancers and Discovery of Novel Predictive Biomarkers will be presented on Tuesday November 17th from 4:30 - 5:30 PM during the Proffered Paper Session.
  • Establishment and Characterization of Primary Human Biomerk Tumorgraft Models: Application to Oncology Drug Development will be presented on Monday November 16th from 12:30 - 2:30 PM and 5:30 - 7:30 PM during the poster session (Abstract #A25).

For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.

www.championsbiotechnology.com

www.personalizedcancertreatment.com

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-K for the fiscal year ended April 30, 2009 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law.

    CONTACT:
    The Investor Relations Group, Inc.
    James Carbonara
    +1-212-825-3210

SOURCE Champions Biotechnology, Inc.


'/>"/>
SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
4. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
7. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
8. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
9. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
10. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
11. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... and applications consulting for microscopy and surface analysis, Nanoscience Instruments is now ... Analytical offers a broad range of contract analysis services for advanced applications. ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
Breaking Biology News(10 mins):